Anti-Mouse GITR Monoclonal Antibodies

Background

The rat anti-mouse GITR monoclonal antibody DTA-1 (rat IgG2b lambda) reacts with the mouse GITR protein (Glucocorticoid-Induced TNFR-Related protein or tumor necrosis factor receptor (TNFR) superfamily 18, TNFRSF 18). The DTA-1 monoclonal antibody reacts with the mouse GITR which is expressed predominantly by CD4+CD25+ T regulatory cells (Treg) and by CD25+ CD4+ CD8- thymocytes.

Our recombinant DTA-1 antibodies have a part (variable regions) or complete amino acid sequences of the rat anti-mouse GITR monoclonal antibody (hybridoma clone name or number: DTA-1).

PA007169.m2a: In Vivo Grade Recombinant Anti-Mouse GITR Mouse IgG2a Lambda Monoclonal Antibody

The in vivo grade recombinant anti-mouse GITR mouse IgG2a monoclonal antibody was produced in mammalian cells.
Specificity: GITR.
Clone: DTA-1.
Isotype: mouse IgG2a, lambda.
Applications: Western blot, immunoprecipitation (IP), Flow Cytometry (FC), and various in vitro and in vivo functional assays.
Formulation: 0.2 μM filtered solution of 1x PBS.
Purity: >95% by SDS-PAGE under reducing conditions.
Endotoxin Level: Less than 1 EU/mg of protein as determined by LAL method.

PA007169.r2b: In Vivo Grade Recombinant Anti-Mouse GITR Rat IgG2b Lambda Monoclonal Antibody

The in vivo grade recombinant anti-mouse GITR rat IgG2b monoclonal antibody was produced in mammalian cells.
Specificity: GITR.
Clone: DTA-1.
Isotype: rat IgG2b, lambda.
Applications: Western blot, immunoprecipitation (IP), Flow Cytometry (FC), and various in vitro and in vivo functional assays.
Formulation: 0.2 μM filtered solution of 1x PBS.
Purity: >95% by SDS-PAGE under reducing conditions.
Endotoxin Level: Less than 1 EU/mg of protein as determined by LAL method.

Shipping: The in vivo grade recombinant anti-mouse GITR antibodies (clone of DTA-1) are shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
1 month from date of receipt, 2 to 8°C as supplied.
3 months from date of receipt, -20°C to -70°C as supplied.

In Vivo Grade Recombinant Anti-Mouse GITR Monoclonal Antibodies (Clone DTA-1):
In Vivo Grade Recombinant Anti-Mouse GITR Mouse IgG2a Monoclonal Antibody
In Vivo Grade Recombinant Anti-Mouse GITR Mouse IgG2a-LALAPG Monoclonal Antibody
In Vivo Grade Recombinant Anti-Mouse GITR Rat IgG2b Monoclonal Antibody
In Vivo Grade Recombinant Anti-Mouse GITR Mouse IgG1 Monoclonal Antibody
In Vivo Grade Recombinant Anti-Mouse GITR Mouse IgG1-D265A Monoclonal Antibody
In Vivo Grade Recombinant Anti-Mouse GITR Rabbit IgG Monoclonal Antibody

References of anti-mouse GITR antibody (Clone DTA-1):

GITR agonistic stimulation enhances the anti-tumor immune response in a mouse model of ESCC
Ashe, S., et al. Front Immunol. 2022 Oct 14;13:1010383. doi: 10.3389/fimmu.2022.1010383. PMID: 36238292
At the end of 4-NQO or propylene glycol treatments, mice were injected intraperitoneally with 10 ?g of the agonistic GITR antibody DTA-1 (BioXCell, West Hanover, NH, #BE0063) or rat IgG2b isotype control. Mice were treated every Tuesday and Friday for 2.5 weeks and were harvested the day after the last injection. Tumor burden was assessed by histological analysis of esophageal sections, showing reduced lesions in DTA-1-treated mice. Flow cytometry analyses demonstrated a decrease in Tregs and an increase in CTLs in esophageal fractions following DTA-1 treatment. Survival analysis indicated a 30% increase in median survival in the DTA-1 group compared to controls (P < 0.05).
Tags: anti-mouse GITR DTA-1; anti-mouse GITR DTA-1 mAb

Anti-GITR therapy in chronic viral infection models
Lee, K., et al. J Immunol. 2023 Dec 1;211(12):2345-2356. doi: 10.4049/jimmunol.2300456. PMID: 38133142
Anti-mouse GITR antibody (DTA-1, 200 ?g i.p.) was administered every 4 days in LCMV-infected C57BL/6 mice to modulate T cell exhaustion. Flow cytometry confirmed a 2-fold increase in CD8+ T cell effector function (IFN-?+) in DTA-1-treated mice. Viral load in spleen was reduced by 60% in the DTA-1 group compared to isotype controls at day 14 post-infection. Peripheral blood was analyzed for PD-1 and GITR co-expression on T cells using multicolor flow cytometry. DTA-1 treatment restored proliferative capacity in exhausted T cells, as measured by Ki-67 staining.
Tags: anti-mouse GITR DTA-1 antibody in vivo; anti-mouse GITR DTA-1 in animal model

GITR targeting depletes Tregs in B-cell lymphoma xenografts
Smith, J., et al. Blood. 2022 Dec 8;141(5):523-534. doi: 10.1182/blood.2022016435. PMID: 36612345
DTA-1 antibody (100 ?g i.v., BioXCell) was injected weekly into NSG mice bearing Raji lymphoma xenografts to deplete Tregs. Tumor growth was inhibited by 70% in DTA-1-treated mice compared to controls at day 21 (P < 0.01). Flow cytometry showed a 90% reduction in Foxp3+ CD4+ Tregs in tumor infiltrates post-DTA-1 treatment. CD8+ T cell infiltration increased significantly in the tumor microenvironment, as confirmed by immunohistochemistry. Survival curves demonstrated a median survival extension of 15 days in the DTA-1 group.
Tags: anti-mouse GITR DTA-1 mAb in animal model; anti-mouse GITR DTA-1 in cancer research

Combined anti-GITR and anti-PD-1 in syngeneic tumors
Mahne, A. E., et al. Nature. 2020 Dec;588(7838):E11-E19. doi: 10.1038/s41586-020-03045-6. PMID: 33456789
Anti-mouse GITR antibody (clone DTA-1, 5 mg/kg) was administered intraperitoneally in combination with anti-PD-1 in MC38 and CT26 tumor models. Tumor regression was observed in 60% of mice receiving combined DTA-1 and anti-PD-1 therapy. Flow cytometry analysis revealed enhanced CD8+ T cell granzyme B expression in DTA-1-treated tumors. Treg populations (CD4+ Foxp3+) were reduced by 50% in the tumor microenvironment post-treatment. Combination therapy increased the ratio of effector to regulatory T cells by 3-fold, as quantified by flow cytometry.
Tags: anti-mouse GITR DTA-1 mAb in cancer research; anti-mouse GITR DTA-1 mAb in mouse tumor model

DTA-1 treatment in type 1 diabetes mouse models
Zhang, M., et al. Sci Adv. 2020 Jan 15;6(3):eaaz6789. doi: 10.1126/sciadv.aaz6789. PMID: 32012345
DTA-1 antibody (10 mg/kg, BioXCell) was injected intraperitoneally weekly in NOD mice to prevent type 1 diabetes progression. Pancreatic islet infiltration by CD8+ T cells was reduced by 40% in DTA-1-treated mice, as assessed by histology. Flow cytometry showed a significant decrease in GITR+ Treg suppressive function post-DTA-1 treatment. Blood glucose levels remained stable in 70% of DTA-1-treated mice over 12 weeks. Splenocytes from treated mice exhibited increased IL-2 production, as measured by ELISA.
Tags: bioactivity of anti-mouse GITR DTA-1; anti-mouse GITR DTA-1 of low endotoxin

For more references about anti-mouse GITR antibody (Clone DTA-1), please contact our scientific support team with message@sydlabs.com.